Latest Earnings Results: Q3 '26
Estimated EPS
-$0.45
Reported EPS
---
Surprise
---
Estimated Rev
$7.55M
Reported Rev
$8.17M
Surprise
+8.2%
• Reported GAAP EPS of -$0.64 up 67.84% YoY • Reported revenue of -$6.67M down -199.10% YoY
Bullish Takeaway
Bionano Genomics demonstrated growth in its core business, highlighted by a 21% increase in total quarterly revenue and expansion of its OGM system installed base and consumable flowcell sales.
Bearish Takeaway
Bionano Genomics faces substantial doubt regarding its ability to continue as a going concern, characterized by recurring net losses, negative cash flows, and ongoing regional growth headwinds in Asia Pacific.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.45 | -- | -- | N/A |
Q2 '26 | -$0.67 | -- | -- | N/A |
Q1 '26 | -$0.88 | -- | -- | N/A |
Q4 '25 | -$2.47 | -- | -- | N/A |
Q3 '25 | -$2.08 | -$2.49 | -20.00% | MISSED |